Once Daily
  • Home
  • About
    • Contact
  • Innovations
    • 3D Printing
    • Artificial Intelligence
    • Diagnostics
    • eHealth
    • Genomics & Precision Medicine
    • Health Sensors & Wearables
    • Medtech
    • Smartphone & Voice Apps
    • Telemedicine
    • Virtual Reality
    • Reviews
  • Community
  • 15 Minutes with the Doctor
Follow Us
Community
Once Daily
Once Daily
  • Home
  • About
    • Contact
  • Innovations
    • 3D Printing
    • Artificial Intelligence
    • Diagnostics
    • eHealth
    • Genomics & Precision Medicine
    • Health Sensors & Wearables
    • Medtech
    • Smartphone & Voice Apps
    • Telemedicine
    • Virtual Reality
    • Reviews
  • Community
  • 15 Minutes with the Doctor
  • Genomics & Precision Medicine

Vivid Genomics is advancing dementia drug development

  • 9 August 2020
  • Once Daily
Vivid Genomics
Location: United States

Alzheimer’s patients tend to have variations in the forms and progression of their disease, which has made drug development a challenge. By isolating differences and working towards more targeted drug development, precision medicine can be applied.

In the past 20 years, over 150 attempts to develop a drug for Alzheimer’s disease have failed. Neurodegenerative diseases, especially Alzheimer’s, are particularly difficult to create new medicines. This is partially due to how much variation is present between patients as there are subtypes, differing rates of progression and people can have different types of dementia.

Vivid Genomics is applying precision medicine to dementia drug development. Targeting variations of the disease rather than looking for a one-size-fits-all treatment should increase drug efficacy and save researchers time and money. Through machine-learning and genomics, they have developed a ‘Genomic Biopsy’ test to identify variations in dementia patients.

By targeting specific traits, researchers can more precisely engineer their drugs and trial them with patients who have the specific change. Currently, there are two tests available – The first checks for amyloid plaques which are typically seen in the condition. The second test predicts the rate of Alzheimer’s disease progression.

Website: https://www.vividgenomics.com/
Email: info@vividgenomics.com
Image: Vivid Genomics

Previous Article
Heal App - Telehealth & House Calls
  • Telemedicine

Heal lets people book house calls from their smartphone

  • 8 August 2020
  • Once Daily
Read More
Next Article
Zipline - Drone Delivery Service
  • Medtech

Zipline is using drones to deliver vital medical supplies in Africa

  • 10 August 2020
  • Once Daily
Read More

Join our network of founders, healthcare professionals, investors and
many others with access to our community only content.



Your privacy is important to us. We hate SPAM and promise to keep your email address safe. By clicking Sign up, you are agreeing to our terms of use.

© Copyright Once Daily. All Rights Reserved.
  • About
  • Privacy
  • Terms

Input your search keywords and press Enter.

Register now to join like-minded
people who are using technology
to redefine healthcare






Your privacy is important to us. We hate SPAM and promise to keep your email address safe. By clicking Sign up, you are agreeing to our terms of use.